Starting Big

Increasing fund size, a depressed but competitive public stock market, and rule-bound money managers unable to even consider investing in small firms are compelling private investors to seek new, deliberately big models for start-up firms. Some VCs are making long-term bets on star-powered teams of people trying to integrate brand-new technologies. If fully-formed start-ups can dramatically improve the drug discovery process, and retain the value they build, they stand to enjoy huge step-ups in valuation when they eventually do go public. Investors seeking faster-than-average returns think they can quickly build integrated-technology companies by buying the basic underpinnings at discount-for instance, by acquiring experienced research groups from major drugmakers anxious to cut costs-then quickly taking the start-ups public. In-licensing may also offer a faster route to ROI. Investors are updating the old model, applying stacks of cash to help certain start-ups acquire operating infrastructure, and reach for big opportunities. Backers expect that big-name founders will be able to net products that elude less experienced people.

by Deborah Erickson

Most venture capitalists' modus operandifor company-building in the drug industry is to start small. A lead investor gives someone with...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.